Dr. Kasahara is the Alvera L. Kan Endowed Chair and Professor of Neurological Surgery and Radiation Oncology at the University of California, San Francisco (UCSF). He obtained his MD in 1986 from Tokyo Medical & Dental University in Japan, and completed PhD research and clinical residency with Board certification in Laboratory Medicine / Clinical Pathology at UCSF. Dr. Kasahara was previously on the faculty at the University of Southern California (USC) and University of California, Los Angeles (UCLA), where he established and directed Vector Core facilities at both institutions for over 18 years, and the University of Miami (UM), where he served as Co-Leader of the Viral Oncology Program. He is also Associate Medical Director of the VRL Eurofins HLA Clinical Laboratory, a reference lab for the regional organ procurement organization, OneLegacy. Dr. Kasahara has >30 years of experience in genetic engineering and gene therapy, and he has authored >140 peer-reviewed research articles. He has served on numerous scientific review panels (including NIH, NCI Canada, Cancer Research UK), and currently serves on advisory boards for the American Society of Gene & Cell Therapy (ASGCT), Japan Society of Gene & Cell Therapy (JSGCT), and OneLegacy. Dr. Kasahara’s research spans the fields of gene therapy, transplantation immunology, and regenerative medicine. In particular, he has pioneered the development of tumor-selective retroviral replicating vectors (RRV) for gene therapy and immunotherapy of cancer, currently being evaluated in an international Phase III registrational trial sponsored by Tocagen Inc. for patients with recurrent high-grade glioma.